Taurine as a Marker for the Identification of Natural Calculus Bovis and Its Substitutes
Calculus Bovis (C. Bovis) is a commonly used animal-derived therapeutic preparation. To meet the increasing clinical demand for the preparation, two artificial substitutes for Bos Taurus have been introduced in China: artificial C. Bovis and in vitro cultured C. Bovis. However, information on their efficacy and safety is inadequate. Therefore, we investigated the biological differences between the commonly used natural preparation and its two substitutes, with the aim of not only identifying the differences but also providing a procedure to distinguish between the different preparations.
In the study, we prepared 9 natural C. Bovis, 2 artificial C. Bovis, and 2 in vitro cultured C. Bovis preparations for evaluation. Differences were noted between the three preparations relative to their effect on viability of cardiac fibroblasts from 1-day-old Wistar rats. Although natural C. Bovis had no effect on cell viability, 1-h treatment of the cells with 0.25 mg/ml of the substitutes significantly reduced cell viability, as detected by the MTS assay. Based on liquid chromatography and inductively coupled plasma mass spectrometry, the preparations also differed in composition. Indeed, the substitutes contained more taurine, cholic acid, iron, magnesium, and calcium than the natural preparations. They also differed spectroscopically.
The present results reveal significant biological differences between natural C. Bovis and two of its substitutes. Since the substitutes appear to contain more taurine, cholic acid, and elements, these constituents may serve as markers to distinguish between natural C. Bovis and its substitutes.
KeywordsZinc Toxicity Magnesium DMSO Manganese
Inductively coupled plasma mass spectrometry
Kyoto University Research Reactor Institute
Principal components analysis
We thank Mr. Yoichi Yokota for the support of the materials, and Dr. Tadashi Saito for help with ICP-MS. This study was supported by a Grant-in-Aid for “Scientific Research (B),” No. 22300310, in 2010–2012 from the Japan Society for the Promotion of Science (JSPS). Partial support was also provided by Grant-in-Aid for JSPS Fellows, No. 23·2852, in 2011–2012 from JSPS.
- Chinese Pharmacopoeia Committee of People’s Republic of China (2010) Pharmacopoeia of the People’s Republic of China, 2010th editionGoogle Scholar
- Hitachi High-Technologies Corporation; Analysis of bile acids in Bovine gallstone, Niuhuang in Chinese and Go-o in Japanese, by LaChrom Ultra. https://members.hht-net.com/sinavi/Menu/Appli/PDF/LCU100002.pdf
- Ministry of Health, Labour and Welfare (2011) The JapanesePharmacopoeia 16th editionGoogle Scholar
- Okasaka M (2008) Farumashia The Pharmaceutical Society of Japan 44:990–991Google Scholar
- Takahashi K, Ouyang X, Komatsu K, Nakamura N, Hattori M, Baba A, Azuma J (2002) Sodium tanshinone IIA sulfonate derived from Danshen (Salvia miltiorrhiza) attenuates hypertrophy induced by angeotensin II in cultured neonatal rat cardiac cells. Biochem Pharmacol 64:745–750PubMedCrossRefGoogle Scholar
- Takahashi K, Azuma Y, Kobayashi S, Azuma J, Takahashi K, Schaffer SW, Hattori M, Namba T (2008) Tool from traditional medicines is useful for health-medication: Bezoar Bovis and taurine Taurine 7. Springer, New York, pp 109–118Google Scholar
- Wójcik OP, Koenig KL, Zeleniuch-Jacquotte A, Pearte C, Costa M, Chen Y (2012) Serum taurine and risk of coronary heart disease: a prospective, nested case–control study. Eur J Nutr. doi:10.1007/s00394-011-0300-6Google Scholar
- Yamaguchi S, Iwai K, Ohba K, Hisata Y, Sakai E, Tanaka T (2008) Characteristics of CALCULUS BOVIS SATIVUS first introduced in the Chinese Pharmacopoeia 2005 Edition. The Japan J Pharmacog 62:15–18Google Scholar